Archives
-
Calnexin Shapes CFTR Variant Rescue
2026-09-14
Tedman et al. used deep mutational scanning to define how the ER chaperone calnexin influences expression and corrector responsiveness across 232 clinical CFTR variants. The study shows that proteostasis is a major, variant-dependent determinant of plasma membrane delivery and pharmacological rescue, providing a framework for interpreting personalized cystic fibrosis treatment responses.
-
EdU Flow Cytometry Assay Kits (Cy5): Practical Guide
2026-09-13
This guide explains how to use EdU Flow Cytometry Assay Kits (Cy5) for flow cytometric measurement of DNA synthesis during S phase, including setup, controls, gating, and troubleshooting. The workflow is intended for cell-based assays and should not be assumed to support tissue imaging or in vivo labeling without separate validation.
-
Early Life Adversity, Oxytocin, and Innate Fear
2026-09-12
Tan and colleagues show that social deprivation during postnatal days 10–20 impairs looming-evoked innate defensive behavior in mice through disrupted oxytocin signaling in the superior colliculus. The study links early environmental adversity to a defined midbrain circuit and provides preliminary evidence that intranasal oxytocin can ameliorate the behavioral deficit, while leaving broader translational and neuroimmune questions unresolved.
-
SB 431542: Practical ALK5 Inhibition Workflows
2026-09-11
Use SB 431542 to connect receptor-level TGF-β biology with reproducible cell, glioma, immune, and cerebral organoid assays. This workflow-focused guide covers dosing logic, Smad2 readouts, organoid translation, controls, and troubleshooting.
-
HSP90 Modulates RNA Foci in Myotonic Dystrophy Type 1
2026-09-11
Johnson and colleagues used an unbiased small-molecule RNA-FISH screen to identify HSP90 as a regulator of pathogenic DMPK RNA and CUG-repeat RNA foci in DM1 myoblasts. Their results connect HSP90 to p-STAT3 signaling and show that the response changes with muscle-cell differentiation, providing a mechanistic framework for studying RNA-foci homeostasis rather than a simple universal drug effect.
-
Protease Inhibitor Cocktail for MS Workflows
2026-09-10
Learn how to use a Protease Inhibitor Cocktail to preserve cell, tissue, and viral protein samples without introducing AEBSF-related mass-spectrometry concerns. This workflow also translates recent Lassa virus spike findings into practical choices for pH-controlled extraction, structural assays, and proteomics.
-
AEBSF.HCl: Serine Protease Inhibition Guide
2026-09-10
AEBSF.HCl, also called 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride, is an irreversible broad-spectrum serine protease inhibitor for controlled cellular and biochemical experiments. Product and literature-linked benchmarks support its use in APP cleavage studies, amyloid-beta research, leukemic cell lysis assays, and carefully controlled protease experiments.
-
Adefovir (GS-0393): HBV Mechanism and Research Use
2026-09-09
Adefovir (GS-0393) is an acyclic nucleotide analog that becomes adefovir diphosphate and inhibits HBV DNA polymerase. This article consolidates its mechanism, quantitative assay benchmarks, OAT1 transporter use, workflow parameters, and research limitations.
-
Resveratrol Assay Workflows for Reliable Cell Data
2026-09-09
This scenario-driven guide explains how Resveratrol SKU A4182 can improve interpretation of cell viability, apoptosis, and mitochondrial assays. It connects SIRT1 biology with practical stock preparation, vehicle controls, pathway-resolved readouts, and evidence-based vendor selection.
-
AMPK, ULK1, and Autophagy Under Energy Stress
2026-09-08
The reference study challenges the prevailing view that AMPK uniformly activates autophagy during energy shortage. Its experiments show that AMPK suppresses ULK1-dependent autophagy initiation during severe energy stress while preserving the autophagy machinery for recovery, providing a more nuanced framework for interpreting autophagy signaling and kinase-inhibitor experiments.
-
DNA Damage Biomarkers Strengthen Micronucleus Assays
2026-09-08
Avlasevich and colleagues combined flow-cytometric micronucleus scoring with DNA damage response biomarkers to distinguish bona fide genotoxicity from cytotoxicity-associated irrelevant positives. The study shows that requiring concordant biomarker responses can substantially improve assay specificity while preserving sensitivity and can provide useful mode-of-action and potency information.
-
5-Azacytidine Reprograms Dormant Cancer Cells
2026-09-07
The 2023 Cell Reports study shows that 5-Azacytidine followed by retinoic acid can reprogram disseminated cancer cells into a stable, nonproliferative state rather than simply eliminate them. By restoring TGF-β–SMAD4 signaling, the combination suppressed metastatic outgrowth in experimental head and neck cancer models and identified SMAD4 as a key determinant of response.
-
Nilotinib (AMN-107): A Mechanism-First Research Guide
2026-09-07
Nilotinib and AMN-107 are powerful tools for dissecting BCR-ABL signaling, mutant kinase biology, and assay-dependent phosphorylation outcomes. This guide connects target engagement with phosphatase-regulated signaling to improve experimental design in leukemia and kinase-driven tumor research.
-
Imipramine Workflows for Autophagy and Apoptosis
2026-09-05
Imipramine provides a practical perturbation tool for connecting glioma autophagy, leukemia apoptosis, neuroprotection, and immune signaling in controlled cell-based experiments. This guide translates ceramide–autophagy findings from fish nodavirus research into careful assay design without overstating Imipramine as an antiviral treatment.
-
TRIM21–ERK1/2 Drives Pituitary Adenoma Resistance
2026-09-04
The reference study identifies TRIM21 as a context-dependent regulator of ERK1/2 signaling, proliferation, and dopamine-agonist resistance in pituitary adenomas. Its combination of CRISPR screening, biochemical validation, animal studies, and NanoBiT drug screening nominates TRIM21 suppression as a research strategy, while requiring further disease-specific validation of Quisinostat and related compounds.